Table 1.

Summary of sample cohort characteristics

Discovery cohortValidation cohort
GroupPathologyGradeStageMenopausal status# PatientsMedian age (IQR)Median CA125 (IQR)# PatientsMedian age (IQR)Median CA125 (IQR)
Healthynonen/an/apostn = 1059.5 (59–60)9.5 (7–12.5)n = 1059.5 (56–65.5)11.5 (8–15)
Benign ASerous cystadenoman/an/apostn = 1062 (57–73)34 (11–50.5)n = 1059.5 (56–62)18.5 (12–36)
Benign BSerous cystadenofibroman/an/apostn = 1070 (57.5–75)14 (12–16)n = 1068 (62–70)10 (9–14)
Early (n = 6)Serous papillary carcinoma3I (a-c)postn = 656 (55.5–56)130.5 (100–243)n = 1057 (53–69.5)113.5 (28–199)
Late (n = 10)Serous papillary carcinoma3IIIcpostn = 1059.5 (56–65)1583.5 (681–3,093)n = 1060 (59–64.5)1,004 (488–1,843)